Clinical Research Directory
Browse clinical research sites, groups, and studies.
Blood-based Biomarkers for Diagnosis of Alzheimer's
Sponsor: Helse Stavanger HF
Summary
Alzheimer's disease (AD) may currently be diagnosed using molecular biomarkers in cerebrospinal fluid (CSF) and/or positron emission tomography (PET). These diagnostic procedures are highly accurate, but the high cost and low availability hamper their feasibility. Recently, ultrasensitive blood tests predicting Alzheimer pathologies in the brain have been developed. These tests have a reliable ability to differentiate AD from other neurodegenerative disorders and identify AD across the clinical continuum with high sensitivity and specificity in research cohorts with a high prevalence of AD. This project will assess the predictive value of these tests in a general practice population. The hypothesis is that the actual blood panel will have high positive predictive value for a diagnosis of Alzheimer's disease in the primary health care setting.
Official title: Accuracy of Blood-based Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice
Key Details
Gender
All
Age Range
40 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
300
Start Date
2023-06-01
Completion Date
2029-12-31
Last Updated
2023-09-28
Healthy Volunteers
No
Conditions
Interventions
predictive value of a blood test
Evaluation of the clinical value of a new blood based test for diagnosis of Alzheimer's disease in a general practice population.
Locations (1)
Stavanger University Hospital
Stavanger, Norway